Merck Patent Gesellschaft MIT Beschrankter Haftung

Merck Patent Gmbh

Astellas Pharma Gmbh

Merck Patent Gesellschaft

Merck Patent Gesellschaft MIT Beschraenkter Haftung

Merck Patent Gellschaft MIT Beschrankter

Hartmut Greiner

Gerd Bartoszyk

Christoph Seyfried

Henning B&ouml;ttcher

Guenter Hoelzemann

Timo Heinrich

Henning Bottcher

Rudolf Gottschlich

Christoph Van Amsterdam

Karl-August Ackermann

Christiane Amendt

Lars Thore Burgdorf

Christina Esdar

Henning Boettcher

Andrew Barber

Andree Blaukat

Bertram Cezanne

Wilfried Rautenberg

Helmut Prucher

Itsuro Shimada

Takashi Sugane

Wataru Hamaguchi

Michel Brunet

Kyoichi Maeno

Ulrich Graedler

Takeshi Suzuki

Junji Miyata

Takahiko Tobe

Maria Kordowicz

Helmut Pr&uuml;cher

Joachim Marz

Tetsuya Kimizuka

Atsuyuki Kohara

Takuma Morita

Michael Arlt

J&uuml;rgen Harting

Kai Schiemann

Hans-Peter Buchstaller

Frank Stieber

Rolf Gericke

Alfred Jonczyk

Frank Zenke

Wolfgang Staehle

Christian Sirrenberg

Dominique Swinnen

Henning Böttcher

Melanie Schultz

Dirk Finsinger

Frank Mauler

Jean-Jacques Berthelon

Michael Gassen

Günter Hölzemann

Jean-Jacques Zeiller

Mireille Krier

Jean Jacques Zeiller

Ralf M Devant

David Bruge

Gerhard Barnickel

Juergen Harting

Anton Haase

Marc Noblet

Helmut Pruecher

Felix Rohdich

Djordje Musil

Joachim M&auml;rz

Karl Ulrich B&uuml;hring

Christopy Seyfried

Per Hillertz

Henning Butcher

Andrew Barbar

Manfred Stohrer

Jean Berthelon

Emilie Rossignol

Lisa Matzen

Joseph Maria Martinez

Compounds of the formula I, in which X1, X2, X3, X4, X5, R1, R2, R3, R4, R5 and R6 have the meanings indicated in Claim, are kinase inhibitors and can be employed, inter alia, for the treatment of tumors.

Bicyclic heteroaromatic compounds

Compounds of the formula (I), in which R, Rand Rhave the meanings indicated in Claim, are kinase inhibitors and can be employed, inter alia, for the treatment of tumors.

Pyrimidine derivatives as FAK inhibitors

The invention relates to compounds of the formula (I), to the preparation and use thereof for the preparation of a medicament for the treatment of diseases, in particular tumors and/or diseases in the development or course of which kinases are involved. 

Azaheterocyclic compounds as kinase inhibitors

Novel imidazo[2,1-b][1,3,4]thiadiazole derivatives of formula (I) 

Imidazothiadiazole derivatives

Novel 5-cyanothienopyridines of the formula (I), in which R, Rand Rhave the meanings indicated in claim, are inhibitors of TGF-beta receptor kinase, and can be employed, inter alia, for the treatment of tumors.

5-cyanothienopyridines for the treatment of tumours

Novel triazole derivatives are inhibitors of TGF-beta receptor I kinase, and can be employed, inter alia, for the treatment of tumours.

Triazole derivatives

Novel triazabenzo[e]azulene derivatives of the formula, (I) in which R, Rand Rhave the meanings indicated in Claim, are inhibitors of TGF-beta receptor kinase and can be employed, inter alia, for the treatment of tumors.

Triazabenzo[E]azulene derivatives for the treatment of tumors

The present invention relates to heterocyclic substituted bisarylurea derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient. 

Heterocyclic substituted bisarylurea derivatives

The invention relates to compounds of the formula (I), to the preparation and use thereof for the preparation of a medicament for the treatment of diseases, in particular tumours and/or diseases in the development or course of which kinases are involved. 

Diazepinoes

The present invention relates to oxindoles of the formula I, their use as protein kinase activators or inhibitors, a method for their manufacture, their use for the preparation of a medicament for the treatment of diseases and their use for the manufacture of a pharmaceutical composition. 

Oxindoles as kinase inhibitors

Benzodioxepines of the formula (I) and physiologically tolerated salts and solvates thereof, in which R, R, R, R, A, B, a and b have the meanings indicated in claim 1, are ligands of the 5HT1A receptors and/or the 5HT4 receptors with simultaneously strong serotonin reuptake inhibition. They can be employed for the treatment and prophylaxis of various diseases 

Substituted benzodioxepines

The invention relates to a triazole derivative with an activity inhibiting glycine transporter and for use as a pharmaceutical drug, and a novel triazole derivative. The inventive triazole derivative has an excellent activity inhibiting glycine transporter and is useful as a therapeutic agent of dementia, schizophrenia, cognitive disorders, or cognitive disorders involved in various diseases such as Alzheimer disease, Parkinson's disease, or Huntington disease or the like, or spasm involved in diseases such as nerve degenerative diseases and cerebrovascular disorders, or the like. Particularly, the pharmaceutical drug is useful for the amelioration of learning disability of dementia and the like.

Triazole derivative

The invention relates to compounds of formula (I), wherein R , R and A have the meanings given in claim 1, are potent 5-HT antagonists and are suitable for treating psychoses, schizophrenia, depression, neurological disorders, impaired memory, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, eating disorders such as bulimia and anorexia nervosa, Pre-Menstrual Syndrome and/or for positively influencing obsessive-compulsive disorders, (OCD).

Piperidine alcohols

Sulfonyloxazoleamines

Growing community of inventors

Weiterstadt, Germany

Hartmut Greiner